LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Artificial Intelligence (AI) Model Identifies COVID-19 Patients Using Blood Tests and Chest X-Rays

By LabMedica International staff writers
Posted on 19 Jul 2021
Print article
Image: Artificial Intelligence (AI) Model Identifies COVID-19 Patients Using Blood Tests and Chest X-Rays (Photo courtesy of Nature)
Image: Artificial Intelligence (AI) Model Identifies COVID-19 Patients Using Blood Tests and Chest X-Rays (Photo courtesy of Nature)
Researchers have developed a machine learning (ML) application for the prediction of SARS-CoV-2 infection using blood tests and chest radiograph.

The ML model developed by researchers at The University of Hong Kong (Hong Kong) was able to achieve high accuracy for the prediction of SARS-CoV-2 infection in a validation study. The adjunctive use of chest radiograph could play a role in increasing sensitivity while achieving moderate specificity when combined with ML blood model, which may have potential implications in triaging patients, particularly when RT-PCR testing resources are scarce.

The objective of this study was to apply ML for the task of COVID-19 detection using basic laboratory markers and explore the adjunctive role of chest radiographs. The researchers initially performed a statistical comparison of blood tests in patients with different aetiologies of pneumonia, including COVID-19 involving 5,148 patients in 24 hospitals in Hong Kong during the first and second waves of infection. This was done to establish a baseline laboratory comparison between COVID-19 from other pneumonia and other diagnoses. The researchers then trained and validated ML models using basic blood tests with comparison to reference RT-PCR testing to predict COVID-19 infection status, and explore different use case scenarios with adjunction of chest radiographs. The models were then validated with temporal validation sets across other waves of infection in Hong Kong.

For predicting SARS-CoV-2 infection, the ML model achieved high AUCs and specificity but low sensitivity in all three validation sets (AUC: 89.9-95.8%; Sensitivity: 55.5-77.8%; Specificity: 91.5-98.3%). When used in adjunction with radiologist interpretations of chest radiographs, the sensitivity was over 90% while keeping moderate specificity. The study showed that ML model based on readily available laboratory markers could achieve high accuracy in predicting SARS-CoV-2 infection.

Related Links:
The University of Hong Kong

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.